Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Avadel Pharmaceuticals

    NASDAQ: AVDL · Real-Time Price · USD
    9.48
    -0.09 (-0.94%)
    At close: Jun 16, 2025, 3:59 PM
    9.45
    -0.36%
    After-hours: Jun 16, 2025, 07:31 PM EDT
    -0.94%
    Bid 9.26
    Market Cap 917.08M
    Revenue (ttm) 194.45M
    Net Income (ttm) -26.41M
    EPS (ttm) -0.26
    PE Ratio (ttm) -36.46
    Forward PE 12.44
    Analyst Buy
    Ask 9.9
    Volume 1,272,862
    Avg. Volume (20D) 1,161,928
    Open 9.35
    Previous Close 9.57
    Day's Range 9.10 - 9.49
    52-Week Range 6.38 - 17.30
    Beta 1.45

    About AVDL

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol AVDL
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for AVDL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    +9.61%
    Avadel Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription
    5 months ago
    -1.57%
    Avadel Pharmaceuticals shares are trading lower after the company announced it sees preliminary Q4 revenues below estimates and issued FY25 net product revenue below estimates.
    news image

    21 hours ago · zacks.com

    Wall Street Analysts See an 81.61% Upside in Avadel (AVDL): Can the Stock Really Move This High?

    The consensus price target hints at an 81.6% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...

    news image

    4 days ago · zacks.com

    Surging Earnings Estimates Signal Upside for Avadel (AVDL) Stock

    Avadel (AVDL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

    news image

    2 weeks ago · zacks.com

    Wall Street Analysts Think Avadel (AVDL) Could Surge 97.68%: Read This Before Placing a Bet

    The average of price targets set by Wall Street analysts indicates a potential upside of 97.7% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positiv...

    news image

    1 month ago · zacks.com

    All You Need to Know About Avadel (AVDL) Rating Upgrade to Buy

    Avadel (AVDL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    news image

    1 month ago · seekingalpha.com

    Avadel Pharmaceuticals: Moving Nicely Through An 'Inflection Year'

    Avadel Pharmaceuticals is gaining momentum with strong Q1 results, a key legal win, and moving swiftly to profitability. LUMRYZ, Avadel's once-daily sodium oxybate, is growing rapidly and could enter ...

    news image

    1 month ago · zacks.com

    Earnings Estimates Moving Higher for Avadel (AVDL): Time to Buy?

    Avadel (AVDL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

    news image

    1 month ago · zacks.com

    Wall Street Analysts Believe Avadel (AVDL) Could Rally 100.21%: Here's is How to Trade

    The mean of analysts' price targets for Avadel (AVDL) points to a 100.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...

    news image

    1 month ago · seekingalpha.com

    Avadel Pharmaceuticals plc (AVDL) Q1 2025 Earnings Call Transcript

    Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q1 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants Austin Murtagh - IR Greg Divis - CEO Tom McHugh - CFO Conference Call Participant...

    Add to Watchlist